Skip to search formSkip to main contentSkip to account menu

trebananib

Known as: trenananib 
An angiopoietin (Ang) 1 and 2 neutralizing peptibody, with potential antiangiogenic activity. AMG 386 targets and binds to Ang1 and Ang2, thereby… 
National Institutes of Health

Related topics

Related topics

4 relations

Narrower (1)

AMG 386

Broader (3)

Angiogenesis InhibitorsPharmacologic SubstanceRecombinant Fusion Proteins

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Phase 2 and biomarker study of trebananib, an angiopoietin‐blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma
Angiopoietins contribute to tumor angiogenesis and may be upregulated as a compensatory factor after vascular endothelial growth… 
2017
2017
Phase II Study of First‐Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma
Abstract Lessons Learned. Trebananib leveraging anti‐angiogenic mechanism that is distinct from the classic sorafenib anti… 
Highly Cited
2015
Highly Cited
2015
Photoacoustic Tomography Detects Early Vessel Regression and Normalization During Ovarian Tumor Response to the Antiangiogenic Therapy Trebananib
The primary aim of this study was to assess the potential of in vivo photoacoustic tomography for direct functional measurement… 
Review
2015
Review
2015
Antiangiogenic agents in gynecological cancer: State of art and perspectives of clinical research.
2015
2015
Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma
IntroductionAngiosarcomas are rare malignant endothelial cell tumors which have up-regulation of the angiopoietin system [e.g… 
Review
2014
Review
2014
Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review
As increased angiogenesis has been linked with the progression of ovarian cancer, a number of anti-angiogenic agents have been… 
2014
2014
Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): A randomised, multicentre, double-blind, placebo-controlled phase 3 trial
Author(s): Monk, BJ; Poveda, A; Vergote, I; Raspagliesi, F; Fujiwara, K; Bae, DS; Oaknin, A; Ray-Coquard, I; Provencher, DM… 
2013
2013
Development of a biosensor-based immunogenicity assay capable of blocking soluble drug target interference.
Highly Cited
2013
Highly Cited
2013
Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer.
BACKGROUND We evaluated AMG 386, an investigational peptibody that neutralizes the interaction between angiopoietins-1 and -2 and… 
2012
2012
Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors
PurposeTo evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of trebananib (AMG 386)—a first-in-class… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)